Coriolus Versicolor and Ganoderma Lucidum Related Natural Products as an Adjunct Therapy for Cancers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Cancer incidence and mortality rates keep rising globally. Coriolus versicolor and Ganoderma lucidum related natural products are commonly applied as a complementary therapeutic option for different stages and types of cancers. The aim of this study is to evaluate the efficacy and safety of the products for cancer therapy.
Methods: Randomized controlled trials were identified by systematic search over seven databases from inceptions to May 10, 2019. Two independent reviewers extracted data and assessed the study quality. Meta-analyses were performed to pool hazard ratio (HR), risk ratio (RR), mean differences (MD), and 95% CI using random-effects models. The sources of heterogeneity were explored by subgroup analyses and sensitivity analyses. Publication bias was detected by Funnel plots, Begg’s test, and Egger’s test.
Results: Twenty-three trials involving 4,246 cancer patients were included in this work. C. versicolor and G. lucidum related natural products were significantly associated with lower risks of mortality (HR: 0.82; 95% CI: 0.72, 0.94) and higher total efficacy (RR: 1.30; 95% CI: 1.09, 1.55), but not associated with control rate (RR: 1.05; 95% CI: 0.96, 1.14) compared with control treatment. There was no significant difference between C. versicolor related natural products and control treatment in the effect on relapse-free survival (HR: 1.19; 95% CI: 0.91, 1.55). Compared with control treatment, C. versicolor and G. lucidum related natural products had a favorable effect on elevated levels of CD3 (MD: 9.03%; 95% CI: 2.10, 16.50) and CD4 (MD: 9.2%; 95% CI: 1.01, 17.39), but had no effect on the levels of CD8 (MD: −5.52%; 95% CI: −23.17, 12.13), CD4/CD8 (MD: 0.73; 95% CI:-0.45, 1.91), or NK(MD: 5.87%; 95% CI: −1.06, 12.8).
Conclusion: In this meta-analysis, we found that C. versicolor and G. lucidum related natural products might have potential benefits on the overall survival and quality of life in cancer patients.
CITE THIS COLLECTION
REFERENCES
- https://doi.org//10.2307/2533446
- https://doi.org//10.1089/acm.2016.0136
- https://doi.org//10.1155/2014/252171
- https://doi.org//10.1016/S0024-3205(96)00695-9
- https://doi.org//10.1136/bmj.315.7109.629
- https://doi.org//10.1177/030006058901700205
- https://doi.org//10.1053/j.seminoncol.2012.02.006
- https://doi.org//10.3969/j.issn.1671-7813.2013.09(x).25
- https://doi.org//10.1002/14651858.CD007731.pub2
- https://doi.org//10.3969/j.issn.0253-9926.2007.07.027
- https://doi.org//10.1155/2012/803239
- https://doi.org//10.3321/j.issn:1000-2790.2002.03.025
- https://doi.org//10.3969/j.issn.0256-7415.2008.04.012
- https://doi.org//10.1200/JCO.1990.8.7.1277